Kamada (NASDAQ:KMDA) Sees Strong Trading Volume – Still a Buy?

Kamada Ltd. (NASDAQ:KMDA) shares saw unusually-strong trading volume on Friday . Approximately 79,100 shares traded hands during mid-day trading, an increase of 2% from the previous session’s volume of 77,826 shares.The stock last traded at $8.8010 and had previously closed at $8.67.

Analysts Set New Price Targets

KMDA has been the subject of several recent research reports. Benchmark reiterated a “buy” rating on shares of Kamada in a report on Tuesday, July 21st. William Blair set a $15.00 target price on Kamada in a research note on Tuesday, July 21st. Weiss Ratings cut Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 25th. UBS Group restated a “buy” rating and set a $15.00 price objective on shares of Kamada in a research note on Friday. Finally, Wall Street Zen upgraded Kamada from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Kamada presently has a consensus rating of “Buy” and a consensus target price of $13.50.

Kamada Stock Performance

The firm has a market cap of $508.45 million, a price-to-earnings ratio of 23.28, a price-to-earnings-growth ratio of 0.67 and a beta of 0.88. The firm’s 50 day moving average is $7.67 and its 200-day moving average is $7.90.

Kamada (NASDAQ:KMDA) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.11 by $0.05. The company had revenue of $54.92 million for the quarter, compared to the consensus estimate of $50.84 million. Kamada had a net margin of 11.60% and a return on equity of 8.37%. As a group, research analysts predict that Kamada Ltd. will post 0.49 EPS for the current year.

Kamada Cuts Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, September 17th. Stockholders of record on Thursday, August 27th were given a dividend of $0.17 per share. The ex-dividend date of this dividend was Thursday, August 27th. This represents a dividend yield of 206.0%. Kamada’s dividend payout ratio (DPR) is currently 34.21%.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Kamada stock. Aristides Capital LLC boosted its stake in Kamada Ltd. (NASDAQ:KMDA) by 4.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,491 shares of the biotechnology company’s stock after purchasing an additional 1,476 shares during the quarter. Aristides Capital LLC owned about 0.06% of Kamada worth $288,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacture and commercialization of plasma-derived and specialty pharmaceutical products. The company’s portfolio is aimed primarily at treating rare diseases and other conditions requiring replacement or immune-modulating therapies.

Kamada’s principal product is GLASSIA, an intravenous alpha-1 proteinase inhibitor used as augmentation therapy in adults with alpha-1 antitrypsin deficiency, a rare genetic disorder that can cause progressive lung disease.